RG 7256

Drug Profile

RG 7256

Alternative Names: PLX-3603; RG7256; RO-5212054

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Plexxikon
  • Developer Plexxikon; Roche
  • Class Antineoplastics; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Malignant melanoma; Solid tumours

Most Recent Events

  • 16 Oct 2012 Discontinued - Phase-I for Colorectal cancer in Australia (PO)
  • 16 Oct 2012 Discontinued - Phase-I for Colorectal cancer in Denmark (PO)
  • 16 Oct 2012 Discontinued - Phase-I for Colorectal cancer in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top